Career history
2019 – d.d.: Onsagers AS, Patent attorney
2017 – 2019: Zacco Norway AS, Patent attorney
2006 – 2017: Patentstyret – Senior Patent Examiner
2002 – 2006: Universitetet i Oslo, Researcher biotech
Education
1993 – 2001 University in Oslo (UiO), PhD, Biotechnology
1992 – 1993 Ett år ved Imperial College, i London, avdeling for biochemistry
1989 – 1992 Oslo MET, Bachelor, Biotechnology
Publications
Lorenzo PI, Brendeford EM, Gilfillan S, Gavrilov AA, Leedsak M, Razin SV, Eskeland R, Sæther T, Gabrielsen OS (2011) “
Identification of c-Myb Target Genes in K562 Cells Reveals a Role for c-Myb as a Master Regulator
”, Genes Cancer, 2(8):805-17.
Rønneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, Yakhini Z, Gut IG, Lønning PE, Børresen-Dale AL, Gabrielsen OS, Kristensen VN (2011) “
GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas
”, Cancer Res. 2008 Jul 15;68(14):5562-71.
Tone Berge, Vilborg Matre, Elen M. Brendeford, Thomas Sæther, Bernhard Lüscher and Odd S. Gabrielsen (2007) ”
Revisiting a selection of target genes for the hematopoietic transcription factor c-Myb using chromatin immunoprecipitation and c-Myb knockdown
”, Blood Cells Mol Dis, 39(3): 278-86.
Kristin Brevik Andersson, Elisabeth Kowenz-Leutz, Elen M. Brendeford, Ann-Helen Herwig Tygsett, Achim Leutz, and Odd S. Gabrielsen (2003) “
Phosphorylation-dependent down-regulation of c-Myb DNA binding is abrogated by a point mutation in the v-myb oncogene
”, J Biol Chem, 278 (6): 3816-24.
Benoît Pinson, Elen M. Brendeford, Odd S. Gabrielsen, and Bertrand Daignan-Fornier (2001) ”
Highly conserved features of DNA binding between two divergent members of the Myb family of transcription factors
” Nucleic Acid Research, 29(2):1-9.
Elen M. Brendeford, Kristin B. Andersson, Odd S. Gabrielsen (1998) ”
Nitric oxide (NO) disrupts specific DNA binding of transcription factor c-Myb in vitro
” FEBS Letters, 425: 52-56.
Elen M. Brendeford, Astrid Hilde Myrset, Anne B. Hegvold, Maria Lundin and Odd S. Gabrielsen (1997) ”
Oncogenic Point Mutations Induce Altered Conformation, Redox Sensitivity, and DNA binding in the Minimal DNA binding Domain of Avian Myeloblastosis Virus v-Myb
” J Biol Chem, 272 (7): 4436-4443.
Eli Ording, Stine Bergholtz, Elen M. Brendeford and Odd S. Gabrielsen (1996) ”
Flexibility in the second half-site sequence recognised by the c-Myb R2 domain – in vitro and in vivo analysis
” Oncogene 13: 1043-1051.
Elen has a background with a doctorate in biochemistry and molecular biology from the University of Oslo, where she has also worked as a researcher for 5 years. After her 13 years at the University of Oslo as a student, doctoral candidate and researcher, she has worked in the Patent Office for over 10 years. From 2017, she has worked as a patent attorney.
As a patent attorney, she assists in the preparation and prosecution of patent applications, particularly in genetics, immunology, micrometric technology, food technology, diagnostics, patent applications including biosquares and technology in the fishing industry such as feed, marine oils and fish health. She has experience with freedom of action analyzes, intervention analyzes, patent landscapes and gives advice on IP strategy.
Prior to Elen working as a patent attorney, she was a patent examiner for 11 years at the Patent Office. She has broad experience in patent literature search and processing of national and international patent applications (PCT applications). In addition to application processing, Elen frequently gave lectures on patenting in general, IPR strategy and patenting of pharmaceutical and biological inventions. She also gained extensive experience in biosecurity seeking and patenting as a basis for freedom analyzes for large international chemical and pharmaceutical companies.
After Elen graduated from the University of Oslo (UiO) in 2001 with a Ph.D. degree in biochemistry / molecular biology continued to work as a researcher at UiO until 2006. During her doctorate and research period, she studied a protein with a central role in the development of blood cells, which is often deregulated in connection with cancer and then especially leukemia. She has extensive experience with various laboratory techniques from basic molecular biology techniques to more advanced technologies such as siRNA and micrometer matrix technology. As a researcher, she was involved in establishing the micrometer matrix technology in the research group she worked in, and worked for one year as a researcher at the University of Utrecht, The Netherlands.
In 2018, Elen was named “Rising IP Star” by Managing Intellectual Property.